Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics (MCRB)
NASDAQ:MCRB
MCRB Analyst Ratings
Moderate Buy
2 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MCRB Stock 12 Month Forecast
Average Price Target
$10.00
▲(5.15%Upside)
| Highest Price Target$14.00 | Average Price Target$10.00 | Lowest Price Target$6.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Chardan Capital
$6
Hold
-36.91%
Downside
Downgraded
05/08/25
TD Cowen
―
Buy
―
Reiterated
05/07/25
9:15 PM SERES THERAPEUTICS (NASDAQ: MCRB) Buy (1) ESG Target: NA REPORTS Q1; STRATEGIC PARTNERSHIP SEARCH REMAINS ONGOING TO PROGRESS SER-155 THE TD COWEN INSIGHT MCRB reported Q1 financials including a cash balance of $59MM, which in addition to other proceeds from the Vowst sale are expected to fund operations into Q1:26. Seres plans to submit a draft Ph. II protocol for SER-155 for the treatment of BSI in allo-HSCT patients to the FDA this quarter, but requires add'l capital or a partnership to initiate the study. Updates on partner search expected.
Canaccord Genuity
$200→$14
Buy
47.21%
Upside
Reiterated
05/07/25
Piper Sandler
$20
Hold
110.30%
Upside
Reiterated
03/14/25
J.P. Morgan
―
Sell
―
Downgraded
10/23/24
Goldman Sachs
$22
Sell
131.34%
Upside
Reiterated
08/14/24
Seres Therapeutics Inc. (MCRB): 2Q24: Vowst asset sale moving forward. SER-155 data in September. 14 August 2024 | 9:44PM EDT Seres Therapeutics (MCRB) reported 2Q24 results including Vowst sales of $14mn, which was slightly below our $16.0mn estimate. Net loss in the quarter of ($32.9mn) and EPS loss of ($0.22), compared to our loss estimate of ($0.27). Lower operating expenses derived from shifts in R&D expenditure and headcount reductions (~41%) that had been announced in 4Q23, which are estimated to generate savings on an annualized basis of $75-$85mn. A further update was provided last week regarding the June announcement of an agreement to sell the remainder of rights to Vowst to their commercial partner, Nestle.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Chardan Capital
$6
Hold
-36.91%
Downside
Downgraded
05/08/25
TD Cowen
―
Buy
―
Reiterated
05/07/25
9:15 PM SERES THERAPEUTICS (NASDAQ: MCRB) Buy (1) ESG Target: NA REPORTS Q1; STRATEGIC PARTNERSHIP SEARCH REMAINS ONGOING TO PROGRESS SER-155 THE TD COWEN INSIGHT MCRB reported Q1 financials including a cash balance of $59MM, which in addition to other proceeds from the Vowst sale are expected to fund operations into Q1:26. Seres plans to submit a draft Ph. II protocol for SER-155 for the treatment of BSI in allo-HSCT patients to the FDA this quarter, but requires add'l capital or a partnership to initiate the study. Updates on partner search expected.
Canaccord Genuity
$200→$14
Buy
47.21%
Upside
Reiterated
05/07/25
Piper Sandler
$20
Hold
110.30%
Upside
Reiterated
03/14/25
J.P. Morgan
―
Sell
―
Downgraded
10/23/24
Goldman Sachs
$22
Sell
131.34%
Upside
Reiterated
08/14/24
Seres Therapeutics Inc. (MCRB): 2Q24: Vowst asset sale moving forward. SER-155 data in September. 14 August 2024 | 9:44PM EDT Seres Therapeutics (MCRB) reported 2Q24 results including Vowst sales of $14mn, which was slightly below our $16.0mn estimate. Net loss in the quarter of ($32.9mn) and EPS loss of ($0.22), compared to our loss estimate of ($0.27). Lower operating expenses derived from shifts in R&D expenditure and headcount reductions (~41%) that had been announced in 4Q23, which are estimated to generate savings on an annualized basis of $75-$85mn. A further update was provided last week regarding the June announcement of an agreement to sell the remainder of rights to Vowst to their commercial partner, Nestle.
Best Analysts Covering Seres Therapeutics
1 Month
xxx
Success Rate
12/21 ratings generated profit
Average Return
+4.38%
reiterated a xxx
rating 11 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +4.38% per trade.
3 Months
xxx
Success Rate
12/21 ratings generated profit
Average Return
+15.13%
reiterated a xxx
rating 11 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +15.13% per trade.
1 Year
Success Rate
13/21 ratings generated profit
Average Return
+120.50%
reiterated a sell rating 11 months ago
Copying Chris Shibutani's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +120.50% per trade.
2 Years
xxx
Success Rate
16/21 ratings generated profit
Average Return
+223.50%
reiterated a xxx
rating 11 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 76.19% of your transactions generating a profit, with an average return of +223.50% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MCRB Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Mar 25
May 25
Strong Buy
2
2
2
3
3
Buy
3
1
2
2
3
Hold
2
1
0
1
2
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
8
5
4
6
8
Each month's total comprises the sum of three months' worth of ratings.
MCRB Financial Forecast
MCRB Stock Forecast FAQ
What is MCRB’s average 12-month price target, according to analysts?
Based on analyst ratings, Seres Therapeutics’s 12-month average price target is 10.00.
What is MCRB’s upside potential, based on the analysts’ average price target?
Seres Therapeutics has 5.15% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MCRB a Buy, Sell or Hold?
Seres Therapeutics has a consensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
What is Seres Therapeutics’s price target?
The average price target for Seres Therapeutics is 10.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.00 ,the lowest forecast is $6.00. The average price target represents 5.15% Increase from the current price of $9.51.
The highest analyst price target is $14.00 ,the lowest forecast is $6.00. The average price target represents 5.15% Increase from the current price of $9.51.
What do analysts say about Seres Therapeutics?
Seres Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of MCRB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.